iOnctura Expands its Clinical Advisory Board

Geneva, Switzerland, 4th February 2020: iOnctura SA, a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces the addition of new members to its Clinical Advisory Board (CAB) with the appointment of Dr. Hendrik-Tobias Arkenau, Executive Medical Director, Sarah Cannon Research Institute, UK, and Dr. Jordi Rodón Ahnert, Clinical co-director MD Anderson Cancer Center.

These appointments come as the company is poised to enter clinical development of its lead product candidate and continues to evolve into a leading biotechnology company with a diverse and sustainable pipeline. The two new CAB members will add additional expertise in tumour immunology, translational research and clinical drug development with a focus on precision medicine in oncology.

Read more 

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...